The Motley Fool's health-care show Market Checkup focuses this week on cholesterol, one of America's most notable health-care concerns.
High cholesterol may not seem particularly dangerous on the surface, but when you add up the amount of at-risk Americans (71 million) and its link to the nation's most prevalent killer (heart disease, at 600,000 deaths per year), the gravity of the situation becomes quickly apparent. The good news is that pharmaceutical products and healthier lifestyles have contributed to combat this problem head-on.
In this video, health-care analysts David Williamson and Max Macaluso discuss the next wave of high-cholesterol-reducing drugs: PCSK9 inhibitors. These are injected biologic products that are producing startling results in clinical trials. Find out how one woman's genetic defect helped inspire a treatment revolution, which stocks are at the cutting edge of this research, and how doctors may receive this new class of drugs.
Follow David on Twitter: @MotleyDavid.
David Williamson, Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Follow David on Twitter: @MotleyDavid. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.